Individuals vary widely in drug response. Microbes in the human gastrointestinal tract influence drug metabolism at multiple levels, but we cannot currently predict whether an individual's gut microbial community (microbiota) predisposes them towards efficient or inefficient metabolism of almost any drug. The long-term goals of this research program are to understand the mechanisms that create interpersonal variation in human gut microbial communities and to measure how this variation impacts drug metabolism. We describe experiments that will uncover how three general mechanisms (direct bacterial interaction, small molecule exchange, and host modulation of the microbiota) determine microbiome dynamics. First, wildtype and genetically manipulated human gut symbionts will be studied in vitro and in gnotobiotic mouse models. Next, genomic analyses and epidemiological modeling will be used to connect experimental results from genetically tractable human gut anaerobes to the entire microbiome. Defined assemblies of human gut microbes will then be examined in vitro and in gnotobiotic mice in order to test predictions from the experimental and computational data. In parallel, we will also apply these approaches to dissect the consequences of microbiome variation on metabolism of 5-aminosalicylate (5-ASA), a front-line drug for ulcerative colitis that is directly modified by bacterial enzymes. This proposal presents plan to integrate drug responsiveness results from patients initiating or currently taking 5-ASA with in vitro and gnotobiotic animal studies of 5-ASA metabolism by their microbiomes. Together, these studies will provide key mechanistic insights critical for adding or removing species in human gut microbiomes in a predictable and stable manner; for manipulating individuals' microbiomes in order to improve medical therapy, and for measuring the contribution of the microbiome to individual drug responses.

Public Health Relevance

Humans carry enormous gut microbial communities that vary widely between individuals. Because interactions between these bacteria and with the host are not understood, we lack the ability to predict how these communities will function or to manipulate the microbiome to promote health or desired responses to medical therapy. This research program will identify mechanisms that shape microbial community variation and define how this variation impacts drug response.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Unknown (R35)
Project #
1R35GM118159-01
Application #
9071690
Study Section
Special Emphasis Panel (ZGM1-TRN-7 (MR))
Program Officer
Sledjeski, Darren D
Project Start
2016-06-10
Project End
2021-05-31
Budget Start
2016-06-10
Budget End
2017-05-31
Support Year
1
Fiscal Year
2016
Total Cost
$1
Indirect Cost
Name
Yale University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wexler, Aaron G; Schofield, Whitman B; Degnan, Patrick H et al. (2018) Human gut Bacteroides capture vitamin B12 via cell surface-exposed lipoproteins. Elife 7:
Crabill, Emerson; Schofield, Whitman B; Newton, Hayley J et al. (2018) Dot/Icm-Translocated Proteins Important for Biogenesis of the Coxiella burnetii-Containing Vacuole Identified by Screening of an Effector Mutant Sublibrary. Infect Immun 86:
Schofield, Whitman B; Zimmermann-Kogadeeva, Maria; Zimmermann, Michael et al. (2018) The Stringent Response Determines the Ability of a Commensal Bacterium to Survive Starvation and to Persist in the Gut. Cell Host Microbe 24:120-132.e6
Shames, Stephanie R; Liu, Luying; Havey, James C et al. (2017) Multiple Legionella pneumophila effector virulence phenotypes revealed through high-throughput analysis of targeted mutant libraries. Proc Natl Acad Sci U S A 114:E10446-E10454
Verster, Adrian J; Ross, Benjamin D; Radey, Matthew C et al. (2017) The Landscape of Type VI Secretion across Human Gut Microbiomes Reveals Its Role in Community Composition. Cell Host Microbe 22:411-419.e4
Raymann, Kasie; Moeller, Andrew H; Goodman, Andrew L et al. (2017) Unexplored Archaeal Diversity in the Great Ape Gut Microbiome. mSphere 2:
Lim, Bentley; Zimmermann, Michael; Barry, Natasha A et al. (2017) Engineered Regulatory Systems Modulate Gene Expression of Human Commensals in the Gut. Cell 169:547-558.e15
G├╝lden, Elke; Vudattu, Nalini K; Deng, Songyan et al. (2017) Microbiota control immune regulation in humanized mice. JCI Insight 2:
Wexler, Aaron G; Goodman, Andrew L (2017) An insider's perspective: Bacteroides as a window into the microbiome. Nat Microbiol 2:17026